Lithium Carbonate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Lithium Carbonate: From Bipolar Disorder to Pseudoachondroplasia
One-Sentence Summary
Lithium carbonate is a long-established mood stabiliser, originally used for bipolar disorder and related affective disorders, and it is also linked to several joint conditions in the knowledge graph. The TxGNN model predicts it may be effective for pseudoachondroplasia, a rare genetic skeletal disorder. This prediction is supported by 0 clinical trials and 0 publications, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bipolar disorder (the Singapore licence has no indication text; the original indications come from the knowledge graph, which also lists major affective disorder, manic bipolar affective disorder, rheumatoid arthritis, osteoarthritis and juvenile idiopathic arthritis) |
| Predicted New Indication | Pseudoachondroplasia |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available for this report. Lithium is generally known to modulate GSK-3 and Wnt signalling, and these pathways take part in chondrocyte function and cartilage biology. That is background knowledge, not something shown by the data compiled for this report.
Pseudoachondroplasia is caused by COMP gene mutations, which lead to endoplasmic reticulum stress in chondrocytes and a defective cartilage matrix. The data compiled for this report do not support a direct link between lithium and this COMP-related pathology. The high score most likely reflects proximity in the knowledge graph to lithium's skeletal and joint indications (osteoarthritis, arthropathy, juvenile arthritis), not demonstrated biology.
The other top-ranked predictions follow the same pattern. They are rare skeletal dysplasias (for example acromesomelic dysplasia Hunter-Thompson type, brachyolmia and brachydactyly-syndactyly syndrome), and all have scores of about 99.95% to 99.98% but no clinical evidence. Lower-ranked predictions such as Behr syndrome, WHIM syndrome and moesin-deficiency immunodeficiency have plausible but untested hypotheses (neuroprotection, effects on neutrophil counts). Their evidence level is also L5.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature is available for pseudoachondroplasia.
For context, one general review is linked to a lower-ranked prediction, brachyolmia-amelogenesis imperfecta syndrome. It does not show that lithium has been tested for that syndrome.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31888683 | 2019 | Review | Orphanet J Rare Dis | Overview of the evolving therapeutic landscape for genetic skeletal disorders; not specific to lithium |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN01305P | CAMCOLIT-400 TABLET 400 mg | Film-coated tablet (oral) | Not stated in the data compiled for this report |
Safety Considerations
- Disease-level contraindication signals (from the knowledge graph, not label text): kidney disease, hypothyroidism, myxedema, congenital hypothyroidism, diabetes insipidus (including neurohypophyseal and central types), cognitive disorder, psoriasis, parapsoriasis, sudden cardiac arrest, heart conduction disease and pyoureter.
- Drug Interactions: The data compiled for this report list 100 interactions, of which 20 are shown. Major-level interactions are:
- Bupropion
- Lorcaserin
Moderate-level interactions include:
- Antidiabetic agents: acarbose, albiglutide, alogliptin, metformin, pioglitazone, canagliflozin, chlorpropamide
- Others: famotidine, loperamide, mesalazine, balsalazide, morphine, metronidazole, clarithromycin, potassium citrate
Minor-level interactions include doxycycline, epinephrine and acetylsalicylic acid.
Package-insert warnings and contraindications are not available. Please refer to the package insert for full safety information. Lithium has a narrow therapeutic index, so this should be reviewed before any new use is considered.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a very high model score (99.98%). No clinical trials or publications support it, and no mechanistic link to COMP-related pseudoachondroplasia is shown. The same holds for the other nine predictions, all of which are at evidence level L5.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA, which currently block safety screening
- Mechanism-of-action data (for example from DrugBank)
- Preclinical evidence (cell or animal models of COMP-related chondrocyte stress) showing a benefit for lithium
- A literature and trial search aimed specifically at lithium in skeletal dysplasias
- A benefit-risk assessment for a narrow-therapeutic-index drug in a rare, mostly paediatric genetic condition, including renal, thyroid and cardiac monitoring
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.